Drug Database
LI

Livact Jelly (Livact Jelly)

✓ Approved

Ajinomoto · therapeutic agent

What is Livact Jelly?

Livact Jelly is a therapeutic agent developed by Ajinomoto. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivact Jelly
CompanyAjinomoto
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ajinomoto

Therapeutic Indications

Livact Jelly is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Hepatobiliary disordersHepatic cirrhosis✓ Approved
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedFood science and biotechnology2026-08-28

Probiotic cell-based encapsulation of natural pigments for maintaining texture and color quality in functional jelly.

Kim Jihoon J, Bai Jaewoo J

The simultaneous incorporation of probiotics and natural pigments into food matrices often causes undesirable changes in texture and appearance. This study aimed to develop a functional jelly containing probiotics and natural colorants without compromising quality by encapsulating carrot and red paprika extracts within probiotic cells. The extracts were prepared with ethanol solutions of different concentrations and encapsulated into commercial probiotic cells using a vacuum-assisted method. The highest encapsulation efficiencies were obtained at 50% ethanol (58.6% for carrot and 27.2% for paprika). When probiotics and free colorants were added together, the jellies became excessively firm. However, encapsulating the colorants within probiotic cells mitigated this effect, resulting in texture properties similar to the control. The encapsulated pigments also provided uniform and natural color appearance in the jelly. These findings suggest that probiotic cell-based encapsulation enables simultaneous incorporation of probiotics and natural colorants into jelly products while maintaining desirable texture and visual quality. The online version contains supplementary material available at 10.1007/s10068-026-02232-7.

PMID 42662085
Read full article →
PubMedFood science and biotechnology2026-08-28

Upcycling sesame meal by-product into diverse food matrices: physicochemical properties and antioxidant profiling.

Go Jiwon J, Shin Youngjae Y

Sesame meal, a by-product of sesame oil extraction, is rich in protein, dietary fiber, and antioxidant lignans, but remains underutilized. This study evaluated its applicability in structurally distinct food matrices, including energy bars, tofu, and acorn jelly, to explore its potential for sustainable functional food development. Physicochemical properties (color, soluble solid content, and pH), total flavonoids, total phenolics, individual polyphenols, and antioxidant activities were analyzed. The energy bar exhibited the highest soluble solid content, whereas tofu showed the highest pH. The energy bar exhibited the highest total flavonoid (41.92 mg catechin equivalents /100 g) and phenolic content (93.51 mg gallic acid equivalents /100 g), whereas acorn jelly showed the strongest radical scavenging activity. Distinct polyphenol profiles were observed among the products, indicating matrix-dependent differences in antioxidant activity. These findings confirm the feasibility of upcycling sesame meal into diverse food systems and highlight its potential as a sustainable, value-added functional ingredient.

PMID 42662009
Read full article →
PubMedJournal of photochemistry and photobiology. B, Biology2026-08-28

Epigenetic landscape model and signaling pathway of cell differentiation driven by extrinsic photobiomodulation combined with microisland.

Tsai Guan-Ying GY, Klom-In Thipwadee T, Hung Ming-Yu MY, Wang Meng-Jiy MJ et al.

Extrinsic photobiomodulation (EPM) combined with microisland offers a universal approach to induce and direct mesenchymal stem cell differentiation. In this study, the dependencies of differentiation of human umbilical cord Wharton's Jelly mesenchymal stem cells driven by this method on various EPM parameters as well as initial cell stemness were investigated and an epigenetic landscape model was established to explain the results consistently. Furthermore, the signal cascade pathway was studied and it was found that photosensitizer binding to endoplasmic reticulum was the primary receptor and the increase of nuclear Ca2+ level was the second messenger. Moreover, the number, size, and concentration of bromodomain-containing protein 4 (BRD4)-containing nuclear condensates were reduced when the cells were on microislands and treated by EPM, indicating this change was involved in the alteration of epigenetic modification that led to the conversion of cell phenotype.

PMID 42659741
Read full article →
PubMedIn vivo (Athens, Greece)2026-08-28

Therapeutic Efficacy of Co-administered WJ-MSCs and Exosomes in a Rat Pulmonary Fibrosis Model.

Choi Seung Ho SH, Baek Hwa Jin HJ, Kim Hyeong Soo HS, Choi Ji Weon JW et al.

Pulmonary fibrosis lacks therapies capable of reversing established fibrosis. Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) show anti-fibrotic promise but are limited by poor engraftment in the fibrotic microenvironment. Evidence from tissue repair models suggests co-delivery of MSC-derived exosomes improves MSC engraftment. Whether WJ-MSCs and their own exosomes produce complementary anti-fibrotic effects in pulmonary fibrosis remains unknown. This study preliminarily evaluated this hypothesis in vivo. Pulmonary fibrosis was induced in left lungs of male rats using bleomycin. At 21 days after bleomycin injection, animals were assigned to WJ-MSC monotherapy, exosome monotherapy, or combination therapy. At 49 days, these treatment groups, alongside normal and bleomycin-treated controls, were evaluated via gross morphological assessment, lung weight measurement, and histological analysis using Masson's trichrome staining to quantify the fibrotic area. Histological evaluation demonstrated significant fibrotic area expansion in the bleomycin group. While WJ-MSC or exosome monotherapies yielded minimal reduction in fibrotic burden, the combination therapy attenuated the fibrotic area by approximately 50% relative to the bleomycin-treated control, accompanied by a notable restoration of alveolar architecture. Co-administration of WJ-MSCs and their derived exosomes produced substantially greater anti-fibrotic effects than either treatment alone. These preliminary findings suggest exosomes prime the fibrotic microenvironment to enhance WJ-MSC engraftment, with additive paracrine contributions driving superior efficacy. As a single fixed dose at the upper range of previously validated doses was used due to limited animal numbers, future studies with dose-response designs, molecular marker analysis, and functional assessments are warranted.

PMID 42665424
Read full article →
PubMedBrain sciences2026-08-27

Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.

Ganina Anastassiya A, Yerzhigit Naizabek N, Lookin Oleg O, Orassay Aliya A et al.

Modern approaches for post-stroke rehabilitation cover mechanistically different ways-from physiotherapy to digital technologies. Among these approaches, stem cell-based therapy represents probably the most complex but promising strategy. We discuss the current state-of-the-art of using mesenchymal stem cells (MSCs) in post-stroke regenerative therapy. Despite relatively wide use of bone marrow and adipose tissue MSCs, these cells represent a more mature ("adult") state, which limits their proliferative and regenerative potentials. Compared to the "adult" MSCs, less "mature" MSCs obtained from umbilical cord, specifically Wharton's jelly MSCs (WJ-MSCs), demonstrate unique functional capabilities and are free from certain technical and ethical issues. The molecular and cellular mechanisms of action of WJ-MSCs are thoroughly discussed in comparison with abundantly used "adult" types of MSCs. We also comparatively evaluate their preclinical and clinical application for treating post-stroke patients. Recent findings indicate that not only MSCs but also their secretome/exosomes (cell-free product) represent a therapeutically beneficial cellular drug in post-stroke recovery. Specially designed and carefully evaluated protocols, which preserve the bioactivity of the cell-free product intact, are mentioned. Neuroprotective and neuroreparative properties of cell-free products-secretome and exosomes-derived from Wharton's jelly MSCs are summarized. Cell-free products obtained from WJ-MSCs are an innovative adjunct therapy for post-stroke disorders, despite certain challenges and limitations of this type of therapy still present. By further investigation of the molecular composition and biological mechanisms of the WJ-MSC secretome and exosomes, their clinical applicability in neuroinflammatory and neurodegenerative pathologies will be promoted.

PMID 42651087
Read full article →
PubMedStem cell research & therapy2026-08-27

Secreted protein combination GAPDH/S100A8/S100A9 from human expanded potential stem cells counteracts mesenchymal stromal cell senescence.

Feng Qingcai Q, Pang Qianwen Q, Lu Hongyu H, Liu Zijing Z et al.

Human mesenchymal stromal cells (hMSCs) remain the most clinically advanced adult stem cell source; however, their therapeutic potential is limited by rapid replicative senescence during ex vivo expansion. Replicative senescence in hMSCs is characterized by cell cycle arrest, acquisition of senescence-associated β-galactosidase (SA-β-Gal) activity, and secretion of the senescence-associated secretory phenotype (SASP) factors. We investigated whether conditioned medium derived from human extended pluripotent stem cells (hEPSCs), which possess both embryonic and extra-embryonic developmental potential beyond that of conventional embryonic stem cells (hESCs), could attenuate replicative senescence in human Wharton's Jelly-derived MSCs (WJMSCs). Using sequential ultrafiltration (10 kDa and 3 kDa) followed by liquid chromatography-tandem mass spectrometry, we identified several proteins from hEPSC-conditioned medium. We then tested the combination of S100A9/GAPDH/S100A8 proteins for their effects on doxorubicin (DOXO)-induced and replicative senescence. hEPSC-conditioned medium markedly attenuated replicative senescence in hMSCs. Notably, the combination of S100A9/GAPDH/S100A8 proteins not only mitigated doxorubicin-induced senescence but also counteracted replicative senescence, as evidenced by a significant reduction in SA-β-Gal-positive cells and downregulated mRNA expression of senescence-associated genes, including p16, p21, and the SASP factor IL-6. Furthermore, EdU incorporation assays revealed significantly enhanced proliferative capacity following treatment. Collectively, our findings establish a defined protein combination (S100A9/GAPDH/S100A8) that counteracts both replicative and stress-induced senescence, offering a novel, cell-free strategy to enhance the clinical utility of WJMSCs.

PMID 42649524
Read full article →

+7478 more articles available with a free account

Sign up free to view all articles →

Ask about Livact Jelly